<?xml version="1.0" encoding="UTF-8"?>
<p>In previous studies of SARS-VoV-1 and MERS-CoV, IVIg showed clinical benefit with good tolerance, and small case series have suggested a possible benefit in CoVID-19.(
 <xref rid="R39" ref-type="bibr">39</xref>–
 <xref rid="R41" ref-type="bibr">41</xref>) In one, three patients who had deteriorated despite standard therapy, but had not yet been mechanically ventilated, were administered 0.4 g/kg IVIg. All became apyrexial in 1–2 days and pulmonary manifestations improved in 3–5 days.(
 <xref rid="R42" ref-type="bibr">42</xref>) Currently, two randomized controlled trials evaluating the efficacy of high-dose IVIg therapy in severe CoVID-19 have been initiated, which will provide more evidence for use. These can be viewed at 
 <uri xlink:href="http://metaevidence.org/COVID19.aspx" xmlns:xlink="http://www.w3.org/1999/xlink">http://metaevidence.org/COVID19.aspx</uri>.
</p>
